LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Lista de Ações・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Fechado

SetorSaúde

68.31 -0.23

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

67.81

Máximo

68.34

Indicadores-chave
By Trading Economics
Rendimento	292M 150M
Vendas	-75M 377M
P/E Médio do Setor	23.663 49.701
EPS	1.221
Margem de lucro	39.832
Funcionários	423
EBITDA	-63M 218M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+17.8% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	349M 8B
Abertura anterior	68.54
Fecho anterior	68.31

Sentimento de Notícias

By Acuity

12%

88%

11 / 345 Ranking em Healthcare

Halozyme Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

25 de mai. de 2026, 08:24 UTC

Grandes Movimentos do Mercado

Aquisições, Fusões, Aquisições de Empresas

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 de mai. de 2026, 21:22 UTC

Ganhos

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Basic Materials Roundup: Market Talk

25 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Ganhos

Basic Materials Roundup: Market Talk

25 de mai. de 2026, 16:01 UTC

Conversa de Mercado

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 de mai. de 2026, 14:43 UTC

Conversa de Mercado

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 de mai. de 2026, 14:15 UTC

Conversa de Mercado

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 de mai. de 2026, 13:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

25 de mai. de 2026, 12:58 UTC

Conversa de Mercado

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 de mai. de 2026, 12:56 UTC

Conversa de Mercado

Ganhos

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 de mai. de 2026, 12:48 UTC

Conversa de Mercado

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 de mai. de 2026, 12:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 de mai. de 2026, 12:34 UTC

Conversa de Mercado

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 de mai. de 2026, 12:10 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Delivery Hero's Assets Look Strategic -- Market Talk

25 de mai. de 2026, 11:00 UTC

Conversa de Mercado

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 de mai. de 2026, 10:19 UTC

Conversa de Mercado

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 de mai. de 2026, 10:05 UTC

Ganhos

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 de mai. de 2026, 10:04 UTC

Ganhos

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 de mai. de 2026, 10:03 UTC

Ganhos

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 de mai. de 2026, 10:02 UTC

Ganhos

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 de mai. de 2026, 10:01 UTC

Ganhos

Tenaga Nasional 1Q Net Up 3.7% on Year

25 de mai. de 2026, 10:00 UTC

Ganhos

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q EPS MYR0.1883

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q Rev MYR17.1B

25 de mai. de 2026, 09:56 UTC

Ganhos

Tenaga Nasional 1Q Net MYR1.1B

25 de mai. de 2026, 09:38 UTC

Conversa de Mercado

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 de mai. de 2026, 09:33 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

25 de mai. de 2026, 09:33 UTC

Conversa de Mercado

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 de mai. de 2026, 08:55 UTC

Conversa de Mercado

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparação entre Pares

Variação de preço

Halozyme Therapeutics Inc Previsão

Preço-alvo

By TipRanks

17.8% parte superior

Previsão para 12 meses

Média 80.48 USD 17.8%

Máximo 96 USD

Mínimo 66.41 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

11 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.